MOTS-c: The Mitochondrial-Derived Peptide Under Investigation for Metabolic Regulation

A research overview of the 16-amino-acid mitochondrial peptide studied for its role in energy metabolism, exercise adaptation, and age-related metabolic decline.

Overview and Discovery

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It was first described in 2015 by Dr. Changhan David Lee and Dr. Pinchas Cohen at the University of Southern California (USC), with findings published in Cell Metabolism.

The discovery was significant because it challenged a longstanding assumption in molecular biology. Mitochondrial DNA was traditionally believed to encode only 13 proteins (all components of the electron transport chain), 2 ribosomal RNAs, and 22 transfer RNAs. The identification of MOTS-c revealed that mitochondrial DNA contains short open reading frames (sORFs) encoding previously unrecognized bioactive peptides, expanding the known genetic repertoire of mitochondria.

MOTS-c belongs to a class of molecules called mitochondrial-derived peptides (MDPs). Other MDPs include Humanin (discovered in 2001) and six small Humanin-like peptides (SHLP1-6). Together, these peptides represent a form of mitochondrial-to-nuclear communication known as retrograde signaling.

Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015;21(3):443-454. PubMed: 25738459

Structure and Classification

MOTS-c is a 16-amino-acid peptide with the sequence: MRWQEMGYIFYPRKLR. It is encoded by an open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). The peptide is highly conserved across species, suggesting an evolutionarily preserved biological function.

Unlike most mitochondrial gene products, which remain within the organelle to support the electron transport chain, MOTS-c has been detected in the cytoplasm, the nucleus, and in systemic circulation. This distribution profile is consistent with its proposed role as a signaling molecule capable of influencing both local cellular processes and distal tissues.

MOTS-c is found in blood and in multiple mitochondria-containing tissues, including skeletal muscle, adipose tissue, and the pancreas. Circulating levels of MOTS-c have been reported to decline with age in both human serum samples and in publicly available transcriptomic datasets from humans and mice.

Mechanism of Action

The primary mechanism investigated for MOTS-c is its activation of AMP-activated protein kinase (AMPK), a central regulator of cellular energy homeostasis. AMPK acts as a metabolic sensor that responds to changes in the AMP-to-ATP ratio within cells. When AMPK is activated, cells increase glucose uptake and fatty acid oxidation while reducing energy-consuming processes like lipid synthesis.

Kim KH, Son JM, Benayoun BA, Lee C. “The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.” Cell Metabolism. 2018;28(3):516-524.e7. PubMed: 29983246

MOTS-c has also been studied in the context of the folate-methionine cycle and de novo purine biosynthesis. Research suggests it may regulate intracellular levels of the metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator, providing a potential mechanistic link between mitochondrial-encoded signals and metabolic regulation.

Metabolic Research

The original 2015 discovery paper by Lee et al. reported that administration of MOTS-c to mice on a high-fat diet prevented the development of diet-induced obesity and insulin resistance. Treated mice demonstrated improved glucose tolerance, reduced circulating insulin levels, and increased glucose uptake in skeletal muscle tissue.

Subsequent research has expanded these findings. A 2024 systematic review and meta-analysis published in Diabetology & Metabolic Syndrome analyzed seven studies (602 total participants) examining circulating MOTS-c levels across different metabolic states. The analysis found that MOTS-c levels were significantly lower in individuals with metabolic conditions compared to healthy controls.

Zhou Q, Yin S, Lei X, et al. “The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis.” Diabetol Metab Syndr. 2024;16:200. PubMed: 39160618

Lower circulating MOTS-c levels have been reported in type 2 diabetes patients, individuals with gestational diabetes, obese children and adolescents, and those with coronary endothelial dysfunction. These correlational findings do not establish causation but have informed ongoing research into the peptide’s potential role in metabolic regulation.

Exercise and Physical Performance Research

A 2021 study published in Nature Communications by Reynolds, Lee, Cohen, and colleagues provided evidence that MOTS-c is an exercise-induced peptide. The research team collected skeletal muscle and plasma samples from healthy young male volunteers before, during, and after exercise on a stationary bicycle.

In the same study, exogenous MOTS-c treatment significantly enhanced treadmill running capacity in young (2-month), middle-aged (12-month), and old (22-month) mice. The magnitude of effect was consistent across all age groups. The researchers concluded that the mitochondrial genome encodes regulatory instructions that contribute to physical capacity maintenance during aging.

Reynolds JC, Lai RW, Woodhead JST, et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications. 2021;12:470. PubMed: 33473109

A variant of MOTS-c (m.1382A>C) has been identified at higher frequency in populations of Japanese centenarians, suggesting a potential genetic link between mitochondrial-derived peptide function and exceptional longevity. This finding was reported by Fuku et al. in Aging Cell (2015).

Fuku N, Pareja-Galeano H, Zempo H, et al. “The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?” Aging Cell. 2015;14(6):921-923. PubMed: 26426128

Aging and Longevity Research

Mitochondrial dysfunction is recognized as one of the hallmarks of aging. Because MOTS-c originates from the mitochondrial genome and its levels decline with age, it has become a subject of aging research.

In the Reynolds et al. (2021) study, late-life initiated intermittent MOTS-c treatment (beginning at 23.5 months of age, three times per week) significantly improved physical capacity and markers of metabolic health in aged mice. The treatment showed a trend toward increased median (6.4%) and maximum (7.0%) lifespan with a reduced hazard ratio of 0.654, though the authors noted that larger cohorts would be needed to confirm the broader significance of the lifespan effect.

The concept of “mitohormesis,” where low-grade mitochondrial stress promotes healthy adaptation, has been linked to MOTS-c function. Research from the Lee laboratory at USC suggests that MOTS-c may act as a mitochondrial signal that promotes cellular homeostasis under conditions of metabolic stress, potentially contributing to healthy aging when kept in balance.

Cardiovascular Research

A 2025 study published in Frontiers in Physiology by Pham et al. examined the effects of MOTS-c on cardiac mitochondrial function in a type 2 diabetes rat model. The researchers reported that MOTS-c treatment restored mitochondrial respiration per tissue mass in diabetic heart tissue and delayed weight gain in diabetic rats.

A 2025 review published in Experimental and Molecular Medicine by Ran et al. described MDPs including MOTS-c as showing protective effects against oxidative damage, inflammation, and disrupted energy metabolism, processes that drive cardiovascular disease progression. The authors noted that clinical application remains limited by challenges including low bioavailability, poor stability, and high synthesis costs.

Pham T, Taberner A, Hickey AJR, Han JC. “Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.” Front Physiol. 2025;16:1602271. PMC: 12257629

Pancreatic and Diabetes Research

A 2025 study published in Experimental & Molecular Medicine reported that MOTS-c levels decline with aging and cellular senescence in pancreatic islet cells. Treating aged mouse pancreatic islets with MOTS-c reduced markers of cellular senescence by modulating nuclear gene expression and metabolites involved in beta-cell senescence.

The study also demonstrated that MOTS-c treatment improved pancreatic islet function and glucose intolerance in two different mouse models: S961-treated C57BL/6 mice (a type 2 diabetes model) and nonobese diabetic (NOD) mice (a type 1 diabetes model). The authors suggested MOTS-c could potentially act as a senotherapeutic agent in pancreatic tissue.

In human subjects, the same study confirmed that circulating MOTS-c levels are lower in type 2 diabetes patients compared to healthy controls, consistent with earlier correlational data.

Kim KH, et al. “Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.” Exp Mol Med. 2025. PubMed: 40855115

Current Research Status

MOTS-c has not entered human clinical trials and has not been approved for human use by the FDA or any regulatory agency. All efficacy and safety data to date comes from preclinical animal models (primarily mice and rats) and human correlational biomarker studies.

Key limitations identified in the current research include:

• No completed randomized controlled trials in humans
• Low bioavailability and poor stability of the peptide in vivo
• High synthesis costs limiting large-scale research
• Optimal dosing, timing, and administration routes remain undefined
• Long-term safety profiles have not been established in any species
• Lifespan extension data requires confirmation in larger cohorts

At this time, MOTS-c is available to qualified researchers for in vitro and preclinical research applications only.

Laboratory Storage and Handling

Once reconstituted, the solution should be stored at 2-8°C and used within a reasonable timeframe to maintain stability. Avoid repeated freeze-thaw cycles. Handle with standard laboratory PPE in accordance with institutional safety protocols.

Researchers seeking a Peptide Sciences alternative for RUO-grade compounds may evaluate Stackhaus Research as a qualified research peptide supplier.